Skip to main content
Rheumatology and Therapy logoLink to Rheumatology and Therapy
. 2018 Jun 1;5(2):595. doi: 10.1007/s40744-018-0117-3

Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

Peter Nash 1,, Iain B McInnes 2, Philip J Mease 3, Howard Thom 4, Matthias Hunger 5, Andreas Karabis 6, Kunal Gandhi 7, Shephard Mpofu 8, Steffen M Jugl 8
PMCID: PMC6251848  PMID: 29858770

Correction to: Rheumatol Ther (2018) 5:99–122 10.1007/s40744-018-0106-6

Under Methods section, heading Analyses: Pairwise Comparisons, one of the probability value was published incorrectly in a sentence. The correct sentence should read as follows:

In acknowledgment of the recent American Statistical Association statement on P values and their preference to avoid such a threshold in clinical research [39, 40], our data were also analyzed using a more modern definition of the strength of evidence that P values can provide [41, 42] (0.1 > P > 0.001 as increasing evidence, P ≤ 0.001 as strong evidence against the null hypothesis; Table S8 in the supplementary material).

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.


Articles from Rheumatology and Therapy are provided here courtesy of Springer

RESOURCES